Vantas
® (
histrelin implant) is a prescription hormone medication approved to relieve the symptoms of advanced
prostate cancer. It is a small, flexible implant that is surgically inserted beneath the skin, where it slowly releases medication into the body for 12 months. Vantas belongs to a group of medicines called gonadotropin-releasing hormone (GnRH) agonists, or sometimes called luteinizing hormone-releasing hormone (LH-RH) agonists.
Vantas is manufactured by Endo Pharmaceuticals Solutions, Inc.
Vantas is a synthetic (manufactured) version of gonadotropin-releasing hormone (GnRH), a naturally occurring hormone that controls the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland (a tiny gland located beneath the brain). LH and FSH stimulate the production of testosterone in the testes.
Vantas works by overstimulating the pituitary gland, so it does not make as much LH and FSH. As a result, the testes stop making testosterone. This causes testosterone levels to decrease. Most forms of prostate cancer are dependent on testosterone to grow. By reducing testosterone levels, Vantas slows down the growth rate of the cancer cells.
The
Vantas implant is specially formulated to slowly release medicine into the body over a 12-month period. This allows for once-a-year dosing.